JP2025512987A5 - - Google Patents

Info

Publication number
JP2025512987A5
JP2025512987A5 JP2024559383A JP2024559383A JP2025512987A5 JP 2025512987 A5 JP2025512987 A5 JP 2025512987A5 JP 2024559383 A JP2024559383 A JP 2024559383A JP 2024559383 A JP2024559383 A JP 2024559383A JP 2025512987 A5 JP2025512987 A5 JP 2025512987A5
Authority
JP
Japan
Prior art keywords
subject
apoa
lipid
formulation according
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024559383A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025512987A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2023/000183 external-priority patent/WO2023194798A1/en
Publication of JP2025512987A publication Critical patent/JP2025512987A/ja
Publication of JP2025512987A5 publication Critical patent/JP2025512987A5/ja
Pending legal-status Critical Current

Links

JP2024559383A 2022-04-06 2023-04-06 脂質結合タンパク質に基づく複合体を使用して白血球増加、内皮機能不全、および心臓炎を処置する方法 Pending JP2025512987A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263328210P 2022-04-06 2022-04-06
US63/328,210 2022-04-06
PCT/IB2023/000183 WO2023194798A1 (en) 2022-04-06 2023-04-06 Methods for treating leukocytosis, endothelial dysfunction and carditis using lipid binding protein-based complexes

Publications (2)

Publication Number Publication Date
JP2025512987A JP2025512987A (ja) 2025-04-22
JP2025512987A5 true JP2025512987A5 (cg-RX-API-DMAC7.html) 2026-04-14

Family

ID=86732365

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024559383A Pending JP2025512987A (ja) 2022-04-06 2023-04-06 脂質結合タンパク質に基づく複合体を使用して白血球増加、内皮機能不全、および心臓炎を処置する方法

Country Status (10)

Country Link
US (1) US20250255931A1 (cg-RX-API-DMAC7.html)
EP (1) EP4504233A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025512987A (cg-RX-API-DMAC7.html)
KR (1) KR20240171131A (cg-RX-API-DMAC7.html)
CN (1) CN119317440A (cg-RX-API-DMAC7.html)
AU (1) AU2023251245A1 (cg-RX-API-DMAC7.html)
CA (1) CA3247588A1 (cg-RX-API-DMAC7.html)
IL (1) IL316100A (cg-RX-API-DMAC7.html)
MX (1) MX2024012302A (cg-RX-API-DMAC7.html)
WO (1) WO2023194798A1 (cg-RX-API-DMAC7.html)

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5128318A (en) 1987-05-20 1992-07-07 The Rogosin Institute Reconstituted HDL particles and uses thereof
GB8712540D0 (en) 1987-05-28 1987-07-01 Ucb Sa Expression of human proapolipoprotein a-i
US5220043A (en) 1991-03-21 1993-06-15 Ohio University Synthesis of D-erythro-sphingomyelins
SE9103701D0 (sv) 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein
EP0751961A1 (en) 1994-03-22 1997-01-08 Research Corporation Technologies, Inc. Eating suppressant peptides
US6037323A (en) 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en) 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6046166A (en) 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
DK1290013T3 (da) 2000-04-21 2006-06-26 Amgen Inc Apo-A1/All-peptidderivater
US7148197B2 (en) 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7199102B2 (en) 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7144862B2 (en) 2000-08-24 2006-12-05 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
WO2002038609A2 (en) 2000-11-10 2002-05-16 Proteopharma Aps Apolipoprotein conjugates
US7217785B2 (en) 2001-05-09 2007-05-15 The Regents Of The University Of California Cysteine-containing peptides having antioxidant properties
ES2304452T3 (es) 2001-08-20 2008-10-16 Csl Behring Ag Una hdl para el tratamiento de un ictus y de otras condiciones isquemicas.
US7223726B2 (en) 2002-01-14 2007-05-29 The Regents Of The University Of California Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same
MXPA04011312A (es) 2002-05-17 2005-02-14 Esperion Therapeutics Inc Metodo para el tratamiento de desordenes dislipidemicos.
US6953840B2 (en) 2002-07-30 2005-10-11 Esperion Therapeutics, Inc. Methods of using non-human animal Apolipoprotein A-I protein
WO2004073684A2 (en) 2003-02-14 2004-09-02 Children's Hospital & Research Center At Oakland Lipophilic drug delivery vehicle and methods of use thereof
JP5048486B2 (ja) 2004-07-16 2012-10-17 トラスティーズ オブ タフツ カレッジ アポリポタンパク質a1の模倣物とその使用
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
BRPI0614966A2 (pt) 2005-08-26 2016-09-13 Cerenis Therapeutics Holding S A vetor de expressão, bactéria de ácido lático, apolipoproteína isenta de endotoxina, e, método de produção de uma apolipoproteína isenta de endotoxina
US8541236B2 (en) 2006-12-08 2013-09-24 University Of Washington Mutant apolipoprotein A-1 polypeptide with increased resistance to oxidation and reactive carbonyls
WO2008104890A2 (en) 2007-02-28 2008-09-04 Cerenis Therapeutics Holding Sa Compositions and methods for producing apolipoprotein
US9173890B2 (en) 2007-09-20 2015-11-03 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
ES2601830T3 (es) 2007-10-23 2017-02-16 The Cleveland Clinic Foundation Apolipoproteína A-1 resistente a oxidantes y péptidos miméticos
MX2011008599A (es) 2009-02-16 2011-11-18 Cerenis Therapeutics Sa Peptidos mimeticos de la apolipoproteina a-i.
WO2011143362A1 (en) 2010-05-11 2011-11-17 Esperion Therapeutics, Inc. Dimeric oxidation-resistant apolipoprotein a1 variants
LT2673296T (lt) 2011-02-07 2019-02-25 Cerenis Therapeutics Holding Sa Lipoproteino kompleksai ir jų gamyba ir jų panaudojimai
SG11201506456VA (en) 2013-03-15 2015-09-29 Cerenis Therapeutics Holding Sa Methods for the synthesis of sphingomyelins and dihydrosphingomyelins
US9708354B2 (en) 2013-03-15 2017-07-18 Cerenis Therapeutics Holding Sa Methods for the synthesis of sphingomyelins and dihydrosphingomyelins
RU2016144908A (ru) 2014-05-02 2018-06-05 Серени Терапеутикс Холдинг Са Маркеры hdl-терапии
KR20230004605A (ko) * 2020-04-16 2023-01-06 아비오닉스 파마 에스에이 지질 결합 단백질-기반 복합체를 사용하여 급성 상태를 치료하는 방법
AU2021254856A1 (en) * 2020-04-16 2022-11-10 Abionyx Pharma Sa CER-001 therapy for treating kidney disease

Similar Documents

Publication Publication Date Title
Wiswell et al. Bronchopulmonary segmental lavage with surfaxin (KL4-surfactant) for acute respiratory distress syndrome
Jat et al. Surfactant therapy for bronchiolitis in critically ill infants
Ghodrat Lung surfactants
Heptinstall et al. Peripheral neuritis in systemic lupus erythematosus
KR102397379B1 (ko) 자가소화의 치료용의 조성물
Sozo et al. Effects of prenatal ethanol exposure on the lungs of postnatal lambs
Kattwinkel Synthetic surfactants: the search goes on
Arii et al. Acute encephalopathy associated with nontyphoidal salmonellosis
Lal et al. Surfactant respiratory therapy using Surfaxin/sinapultide
Dixon et al. The relationship of neuropathy to the treatment of tuberculosis with isoniazid
Zhou Successful rescue of fulminant myocarditis with mechanical circulatory support and immunosuppression therapy: A case report
Chhikara et al. Glyphosate surfactant herbicide poisoning manifestations and management: a case series
Saboo et al. Chemical pneumonitis and reactive airways dysfunction syndrome after fumigation exposure to dimethanol and glutaraldehyde: a silent menace unmasked
Çarlı Oxygen-ozone autohemotherapy in sacroiliitis
CN110294791B (zh) 具有胆固醇外流活性的抗动脉粥样硬化肽类似物及其应用
JP2002522507A (ja) 疾患状態の処置
Ueno et al. Morphological abnormalities of erythrocyte membrane in the hereditary neurological disease with chorea, areflexia and acanthocytosis: a study with freeze-fracture electron microscopy
CN1264304A (zh) 脂基免疫调节剂组合物
JP2023509520A5 (cg-RX-API-DMAC7.html)
US20250177451A1 (en) Extracellular vesicles for therapy
Davis Physiologic implications of the autonomic aberrations in cystic fibrosis
US20240408173A1 (en) Silk fibroin-containing composition and methods of use thereof
Piloni et al. Current management strategies and the potential of inhaled GM-CSF for the treatment of autoimmune pulmonary alveolar proteinosis
JP2021522263A (ja) 肺サーファクタントおよびbpdの予防のためのステロイドを含む治療的組合せ
Lakkundi et al. Surfactant therapy and SP-D in managing COVID-19 ARDS–therapeutic role possible